Paul F. Robbins
National Institutes of Health
187 Papers
1.5K Citations
Paul F. Robbins is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Antigen & T cell. The author has an hindex of 84, co-authored 187 publications.
Chat about Author
Papers
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.
Drew C. Deniger,Anna Pasetto,Eric Tran,Maria R. Parkhurst,Cyrille J. Cohen,Paul F. Robbins,Laurence J.N. Cooper,Steven A. Rosenberg +7 more
TL;DR: Sleeping Beauty transposition of mutation-specific TCRs can facilitate the use of personalized T-cell therapy targeting unique neoantigens in cancer patients using the clinical Sleeping Beauty transposon/transposase system.
The use of melanosomal proteins in the immunotherapy of melanoma
Yutaka Kawakami,Paul F. Robbins,Rongfu Wang,Maria R. Parkhurst,Xiaoqiang Kang,Steven A. Rosenberg +5 more
TL;DR: Phase I immunization trials using peptides or recombinant viruses containing genes encoding the melanosomal antigens MART-1 or gp100, with or without co-administration of cytokines such as IL-2, IL-12, or granulocyte-macrophage colony-stimulating factor, are being conducted in the Surgery Branch of the National Cancer Institute to demonstrate the feasibility of using melanosome proteins for the immunotherapy of patients with melanoma.
Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice
Christopher E. Touloukian,Wolfgang W. Leitner,Suzanne L. Topalian,Yong F. Li,Paul F. Robbins,Steven A. Rosenberg,Nicholas P. Restifo +6 more
TL;DR: HLA class II transgenic mice may be useful in the identification of helper epitopes derived from Ags of potentially great clinical utility, and the synthetic peptide h-gp10044–59 to sensitize lymphocytes ex vivo.
T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product
TL;DR: Monitoring studies indicated that T cell clones reactive with the mutated HLA-A11 gene product and the mutated p14ARF product were highly represented in the peripheral blood of patient 1913 1 wk following adoptive transfer, indicating that they may have played a role in the nearly complete tumor regression that was observed following this treatment.
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.
Yutaka Kawakami,Jane K. Battles,Takeshi Kobayashi,Willis H. Ennis,Xiang Wang,Janis P. Tupesis,Francesco M. Marincola,Paul F. Robbins,Vincent J. Hearing,Matthew A. Gonda,Steven A. Rosenberg +10 more
TL;DR: Subcellular fractionation studies suggested that Mart-1 was present in melanosomes and endoplasmic reticulum, although known melanogenic enzymatic activities were not detected in the MART-1 protein.